Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric ...

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...